Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.
Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.
A 26-year-old man who had a hair transplant and used minoxidil with good results is now experiencing shedding and considering finasteride. He's concerned about high progesterone and mild erectile dysfunction before starting the treatment.
Concerns about finasteride affecting sperm quality and embryo abnormalities during IVF. The user plans to stop finasteride for 6 months and use minoxidil, microneedling, a red light cap, and saw palmetto shampoo to manage hair loss.
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
Topilutamide is a potential hair loss treatment between Clascoterone and RU58841. Users discuss finding Topilutamide powder and its possible benefits for those who can't afford or tolerate other treatments.
The conversation discusses the potential for Verteporfin to reduce scarring, making hairline lowering surgeries more viable for men with mild hair loss. The user suggests that if scarring can be minimized, men might opt for hairline lowering instead of using grafts for other areas.
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.
You cannot donate blood if you are taking finasteride or dutasteride due to potential risks to pregnant women. Finasteride has a shorter wait time to donate blood compared to dutasteride, and both oral and topical forms can disqualify you from donating.
A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.
The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.
The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17Ξ±-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.
The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.
The conversation is about concerns regarding the safety of using stemoxydine (Serioxyl Advanced) around cats, with the user also using minoxidil, oral minoxidil, dutasteride, and microneedling for hair loss. The user is seeking advice on whether stemoxydine is toxic or lethal to cats.
The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
Finasteride and dutasteride can cause psychiatric side effects like depression and suicidal thoughts in some users, especially those with a history of mental health issues. While some users experience positive hair growth results, others face severe psychological effects, raising concerns about their safety and the need for careful monitoring.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.
A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
Tretinoin may increase minoxidil absorption but could potentially worsen hair loss over time. Users discuss applying 0.5% tretinoin gel to the hairline/scalp with minoxidil.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
The conversation discusses Verteporfin as a potential hair loss treatment, with trials by Dr. Bargouthi and Dr. Bloxham mentioned, and a suggestion to follow updates on the Hair Restoration Network site or YouTube. Preliminary results are positive, but one user is skeptical, calling it "snake oil."
Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.